Human immunodeficiency virus (HIV) prevalence is increasing worldwide as people on antiretroviral therapy are living longer. These patients are often susceptible to debilitating inflammatory disorders that are frequently refractory to standard treatment. Psoriasis is a systemic inflammatory disorder, associated with both physical and psychological burden, and can be the presenting feature of HIV infection. In this population, psoriasis tends to be more severe, to have atypical presentations and higher failure rates with the usual prescribed treatments. Management of moderate and severe HIV-associated psoriasis is challenging. Systemic conventional and biologic agents may be considered, but patients should be carefully followed up for potential adverse events, like opportunist infections, and regular monitoring of CD4 counts and HIV viral loads.
Keywords: Biological therapies; Conventional systemic therapies; Fototerapia; HIV; Immunosuppression; Inmunodepresión; Phototherapy; Psoriasis; Terapias biológicas; Terapias sistémicas convencionales; Topical therapy; Tratamiento tópico; VIH.
Copyright © 2017 AEDV. Publicado por Elsevier España, S.L.U. All rights reserved.